SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 | 
|---|---|---|---|---|---|---|
| 96.0 | -2.2 | 1 | 3 | 83.0 | 0 | 0.0 | 
- CAS
- 7558794
- UNII
- 22ADO53M6F
- SYNONYMS
- 
                                
- ZINC ID(s)
- 
                            
- Availability
- Present in 0 ZINC catalogs
Known Active Genes
                        
                            There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
                        
                    
                    
                Clinical Trials
                            
                                This compound has not been in (or located in) any clinical trials (per clinicaltrials.gov).
                            
                        
                        
                    (Browse) Purchasable Analogs in ZINC
Dosages
| Route | Formulation | Per Unit Dose | 
|---|---|---|
| Auricular (Otic) | Solution | 0.8% | 
| Buccal | Film | 0.35MG | 
| Im - Iv | Injectable | 1.75% | 
| Im - Iv | Injection | 13.92% | 
| Im - Iv | Powder, For Injection Solution | 13.92% | 
| Intra-Articular | Injectable | 0.71% | 
| Intralesional | Injectable | 0.71% | 
| Intramuscular | Injectable | 0.71% | 
| Intramuscular | Injection | 0.29% | 
| Intramuscular | Powder, For Injection Solution | |
| Intramuscular | Powder, For Injection Solution, Lyophilized | 0.03% | 
| Intravenous | Injectable | 0.24% | 
| Intravenous | Injection | 21.3% | 
| Intravenous | Powder, For Injection Solution | 3.25% | 
| Intravenous | Powder, For Injection Solution, Lyophilized | 1.5% | 
| Intravesical | Solution, Injection | 3.83% | 
| Iv(Infusion) | Infusion | 0.01% | 
| Iv(Infusion) | Injectable | 0.01% | 
| Iv(Infusion) | Injection | 4% | 
| Iv(Infusion) | Powder, For Injection Solution | 13.92% | 
| Iv(Infusion) | Solution, Injection | 0.01% | 
| Nasal | Solution | 0.5% | 
| Nasal | Spray | 0.01% | 
| Nasal | Spray, Metered | 0.5% | 
| Ophthalmic | Solution | 0.46%W/W | 
| Ophthalmic | Solution, Drops | 1.4% | 
| Ophthalmic | Suspension | 0.25% | 
| Oral | Capsule | 300MG | 
| Oral | Capsule, Delayed Release | 4.8MG | 
| Oral | Capsule, Enteric Coated Pellets | 2MG | 
| Oral | Film, Soluble | 0.05MG | 
| Oral | Solution, Syrup | 1.75% | 
| Oral | Suspension | 0.66%W/V | 
| Oral | Syrup | 0.35% | 
| Oral | Tablet | 48MG | 
| Oral | Tablet, Extended Release | 105MG | 
| Oral | Tablet, Film Coated | 0.01MG | 
| Oral | Tablet, Sustained Action | 110MG | 
| Oral | Tablet, Uncoated, Lozenge | 31MG | 
| Oral | Tablet, Uncoated, Troche | 28MG | 
| Subcutaneous | Injectable | 0.1% | 
| Subcutaneous | Powder, For Injection Solution, Lyophilized | 0.03% | 
| Subcutaneous | Solution, Injection | 0.01% | 
| Topical | Emulsion, Aerosol Foam | 0.09% | 
| Topical | Emulsion, Cream | 0.36% | 
| Topical | Gel | |
| Topical | Lotion | |
| Topical | Ointment | |
| Topical | Solution | 0.47%W/V | 
| Topical | Solution, Drops | 0.45%W/V | 
| Vaginal | Cream, Emulsion, Sustained Release | 0.09% |